Search Results
Baxter Receives CE Marking and Australian Regulatory Approval for Evo IQ Syringe Infusion System, Building on Smart Pump Platform
Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced CE marking and regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for the Evo IQ Syringe Infusion System. The company expects hospitals in the United Kingdom, Ireland, Greece, Australia and New Zealand to be among the first to receive the new system, with additional countries to follow in a series of planned regulatory submissions.
Baxter Announces Results of Clinical Trial on Benefits of Dynamic Fluid Management in Septic Shock Patients
Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced results of the Fluid Response Evaluation in Sepsis Hypotension and Shock (FRESH) study using the Starling Fluid Management Monitoring System, recently published in CHEST.
Baxter Increases Dividend and Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock. This represents an approximately 11% increase over the previous quarterly dividend rate of $0.22 per share. Baxter’s Board of Directors declared the dividend payable on July 1, 2020, to stockholders of record as of June 5, 2020.
Baxter Reports First-Quarter 2020 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2020.
Baxter to Present at the UBS Virtual Global Healthcare Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 via webcast. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:00 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 15, 2020.
Baxter Obtains U.S. FDA Emergency Use Authorization for Oxiris Blood Purification Filter for COVID-19 Treatment
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received emergency use authorization (EUA) from the U.S. FDA for the company's Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT).
Baxter to Present at the Virtual BofA Securities 2020 Health Care Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the virtual BofA Securities 2020 Health Care Conference via webcast on Tuesday, May 12, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:20 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through August 10, 2020.
Baxter Shares Progress on Increasing Dialysis Supplies for Critically Ill COVID-19 Patients
Baxter International Inc., a global leader in acute care, today shared updates regarding its efforts to increase supply of critically needed dialysis products around the globe. The company is seeing demand up to five times greater than historical levels for multiple acute dialysis products as a result of an extraordinary rise in COVID-19 patients requiring access to continuous renal replacement therapy (CRRT).
Baxter to Host First-Quarter 2020 Financial Results Conference Call For Investors
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2020 financial results on Thursday, April 30, 2020, at 7:30 a.m. Central Time. To access the call, dial (844) 886-1929 (domestic) or (225) 239-4663 (international). Please dial into the call at least ten minutes prior to the start for the operator to connect you. The Conference ID is 8207759.
Baxter Provides Update on COVID-19 Response Efforts
Baxter International Inc. (NYSE:BAX), a global medical products company, today provided an update on how the company is responding to the COVID-19 epidemic that is challenging communities and healthcare systems throughout the world.